SCHEMBL29614071

SCHEMBL29614071

O=C1CCCC(=O)N1N1Cc2ccccc2C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 3/20 0.41
▸ MAOB P27338 3/20 0.41
▸ CYP2A6 P11509 2/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ KMT2A Q03164 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ AKR1C3 P42330 1/20 0.37
▸ NOTUM Q6P988 1/20 0.36
▸ CES1 P23141 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5969633 1.00 MAOA (0.41) MAOAMAOBCYP2A6RXFP1KMT2A
Hydrochloric Acid SCHEMBL30423571 0.98 MAOA (0.39) MAOAMAOBCYP2A6RXFP1KMT2A
Trifluoroacetic Acid SCHEMBL29148099 0.85 DPP8 (0.38) NOTUMALDH1A1
SCHEMBL3943105 0.79 CYP1A2 (0.50) MAOAMAOBCYP2A6RXFP1KMT2A
SCHEMBL25433262 0.73 SRD5A1 (0.40) MAOAMAOBRXFP1NOTUMALDH1A1
SCHEMBL23832541 0.72 KMT2A (0.67) MAOAMAOBCYP2A6KMT2AMEN1
SCHEMBL29569183 0.72 KMT2A (0.67) MAOAMAOBCYP2A6KMT2AMEN1
Hydrochloric Acid SCHEMBL4557636 0.71 KMT2A (0.65) MAOAMAOBCYP2A6KMT2AMEN1
SCHEMBL30722457 0.71 HPGD (0.49) CYP2A6KMT2AMEN1CYP1A2CYP2C9
SCHEMBL28656618 0.69 KMT2A (0.34) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240743-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Prelude Therapeutics, Incorporated (US) 2023-09-13 — — EP claimed
EP-4126843-A1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2023-02-08 — — EP claimed
WO-2022099117-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE PRELUDE THERAPEUTICS INCORPORATED (US) 2022-05-12 — — WO claimed
CN-119954801-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-05-09 — — CN disclosed
CN-114867727-B TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-02-21 — — CN disclosed
WO-2024123195-A1 TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-06-13 — — WO disclosed
CN-116669769-A Piperidinyl small molecule degradants of HELIOS and methods of use 达纳-法伯癌症研究所公司 2023-08-29 — — CN disclosed
EP-4126843-A1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2023-02-08 — — EP disclosed
Send feedback